Organisation paid for research Program year 2025 Source: CMS Open Payments

California Research Trials

Neither a doctor nor a teaching hospital

Research payments

$595,823

44 payments

Through program year 2025, California Research Trials is reported as receiving $595,823 in research payments, across 44 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $20,786 4
2024 Research $11,949 5
2023 Research $63,901 9
2022 Research $175,424 8
2021 Research $281,787 10
2020 Research $34,475 7
2019 Research $7,500 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $585,812 42 payments
  2. GRT US Holding, Inc. $7,500 1 payment
  3. Novavax Inc $2,511 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $145,838 5 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis $137,766 3 payments
  3. A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $96,731 2 payments
  4. TBC Hepatic Impairment $67,413 1 payment
  5. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $24,729 1 payment
  6. Loxo-Btk-20012-Ph1-Pirtobrutinib-Hepatic $23,198 1 payment
  7. TBC: Renal Impairment $21,333 1 payment
  8. A Phase 3 16-Week Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $12,723 1 payment
  9. A Phase 3 12 Month Open Label Study of Lasmiditan in Pediatric Patients With Migraine Pioneer Peds2 $11,063 2 payments
  10. Loxo-Btk-20013-Ph1-Pirtobrutinib-Renal $9,310 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record